Wire · opportunities
FDA Okays New FGFR2 Inhibitor for Cholangiocarcinoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The FDA approved lirafugratinib for adults with previously treated unresectable, locally advanced, or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements. This FGFR2-selective inhibitor offers a differentiated safety profile compared to existing pan-FGFR inhibitors and showed a 46% objective response rate in clinical trials.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
New FGFR2 inhibitors like lirafugratinib raise the bar on safety and effectiveness standards in cholangiocarcinoma treatment. You in oncology drug development need to factor selective FGFR2 targeting when planning your pipeline or competitive positioning.
◆ Coverage
10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026
◆ Topics